در نوبت چاپ
برگشت به فهرست مقالات |
برگشت به فهرست نسخه ها
شادی حسینی طوسی1 
، هوشنگ رفعت پناه2 ، معصومه سرباز1 ، ریحانه نوروزی اول3 ، سیده فاطمه موسوی بایگی3 ، رضا بوستانی4 ، فریبا زمرشیدی4 ، زهره وحیدی4 ، خلیل کیمیافر5
، هوشنگ رفعت پناه2 ، معصومه سرباز1 ، ریحانه نوروزی اول3 ، سیده فاطمه موسوی بایگی3 ، رضا بوستانی4 ، فریبا زمرشیدی4 ، زهره وحیدی4 ، خلیل کیمیافر5
1- گروه فناوری اطلاعات سلامت، دانشکده علوم پیراپزشکی و توانبخشی، دانشگاه علوم پزشکی مشهد، مشهد، ایران.
2- مرکز تحقیقات ایمونولوژی، بخش التهاب و بیماریهای التهابی، دانشگاه علوم پزشکی مشهد، مشهد، ایران
3- گروه فناوری اطلاعات سلامت، دانشکده علوم پیراپزشکی و توانبخشی، دانشگاه علوم پزشکی مشهد، مشهد، ایران. و کمیته تحقیقات دانشجویی، دانشگاه علوم پزشکی مشهد، مشهد، ایران
4- مرکز تحقیقات ایمونولوژی، بخش التهاب و بیماریهای التهابی، دانشگاه علوم پزشکی مشهد، مشهد، ایران.
5- گروه فناوری اطلاعات سلامت، دانشکده علوم پیراپزشکی و توانبخشی، دانشگاه علوم پزشکی مشهد، مشهد، ایران. ،Kimiafarkh@mums.ac.ir
2- مرکز تحقیقات ایمونولوژی، بخش التهاب و بیماریهای التهابی، دانشگاه علوم پزشکی مشهد، مشهد، ایران
3- گروه فناوری اطلاعات سلامت، دانشکده علوم پیراپزشکی و توانبخشی، دانشگاه علوم پزشکی مشهد، مشهد، ایران. و کمیته تحقیقات دانشجویی، دانشگاه علوم پزشکی مشهد، مشهد، ایران
4- مرکز تحقیقات ایمونولوژی، بخش التهاب و بیماریهای التهابی، دانشگاه علوم پزشکی مشهد، مشهد، ایران.
5- گروه فناوری اطلاعات سلامت، دانشکده علوم پیراپزشکی و توانبخشی، دانشگاه علوم پزشکی مشهد، مشهد، ایران. ،
چکیده: (134 مشاهده)
مقدمه: این مطالعه با هدف تعیین مجموعه داده حداقلی و طراحی سامانه ثبت ویروس تی لنفوتروپیک انسانی نوع ۱ (Human T-cell Lymphotropic Virus type 1: HTLV-1) با قابلیت توسعه در سطح ملی، با تمرکز بر ناقلین و بیماران مبتلا به میلوپاتی مرتبط با HTLV-1 / پاراپارزی اسپاستیک گرمسیری (HTLV-1 Associated Myelopathy / Tropical Spastic Paraparesis: HAM/TSP)، انجام شد.
روشها: این پژوهش یک مطالعه کاربردی با رویکرد ترکیبی (مرور جامع متون و روش دلفی) است که در در دانشگاه علوم پزشکی مشهد انجام شد. ابتدا یک مرور جامع متون از پایگاههای PubMed، Embase، Scopus و Web of Science انجام شد تا عناصر داده مرتبط با HTLV-1 و HAM/TSP استخراج شوند. سپس، عناصر داده شناساییشده در قالب پرسشنامهای ساختیافته تدوین و طی دو دور روش دلفی با مشارکت ۱۹ متخصص اعتبارسنجی شدند. معیار پذیرش عناصر داده، سطح اجماع متخصصان بر اساس مقیاس لیکرت بود. در ادامه، بر اساس مجموعه داده حداقلی نهایی، سامانه ثبت HTLV-1 طراحی شد.
یافتهها: از میان ۹۷ مطالعه واجد شرایط، در مجموع ۲۰۹ عنصر داده برای ناقلین HTLV-1 و ۲۶۰ عنصر داده برای بیماران مبتلا به HAM/TSP استخراج شد. پس از اجرای روش دلفی، مجموعه داده حداقلی نهایی شامل ۱۴۷ عنصر داده در ۱۱ دسته برای ناقلین HTLV-1 و ۱۳۷ عنصر داده در ۹ دسته برای بیماران HAM/TSP تعیین شد. همچنین یک سامانه ثبت مبتنی بر وب بر اساس این مجموعه داده توسعه و بهصورت پایلوت پیادهسازی شد.
نتیجهگیری: در این مطالعه، یک مجموعه داده حداقلی برای ناقلین HTLV-1 و بیماران مبتلا به HAM/TSP تعیین و سامانه ثبت متناظر آن توسعه داده شد که میتواند بستر مناسبی برای ثبت اطلاعات و دادههای مرتبط با HTLV-1 باشد.
روشها: این پژوهش یک مطالعه کاربردی با رویکرد ترکیبی (مرور جامع متون و روش دلفی) است که در در دانشگاه علوم پزشکی مشهد انجام شد. ابتدا یک مرور جامع متون از پایگاههای PubMed، Embase، Scopus و Web of Science انجام شد تا عناصر داده مرتبط با HTLV-1 و HAM/TSP استخراج شوند. سپس، عناصر داده شناساییشده در قالب پرسشنامهای ساختیافته تدوین و طی دو دور روش دلفی با مشارکت ۱۹ متخصص اعتبارسنجی شدند. معیار پذیرش عناصر داده، سطح اجماع متخصصان بر اساس مقیاس لیکرت بود. در ادامه، بر اساس مجموعه داده حداقلی نهایی، سامانه ثبت HTLV-1 طراحی شد.
یافتهها: از میان ۹۷ مطالعه واجد شرایط، در مجموع ۲۰۹ عنصر داده برای ناقلین HTLV-1 و ۲۶۰ عنصر داده برای بیماران مبتلا به HAM/TSP استخراج شد. پس از اجرای روش دلفی، مجموعه داده حداقلی نهایی شامل ۱۴۷ عنصر داده در ۱۱ دسته برای ناقلین HTLV-1 و ۱۳۷ عنصر داده در ۹ دسته برای بیماران HAM/TSP تعیین شد. همچنین یک سامانه ثبت مبتنی بر وب بر اساس این مجموعه داده توسعه و بهصورت پایلوت پیادهسازی شد.
نتیجهگیری: در این مطالعه، یک مجموعه داده حداقلی برای ناقلین HTLV-1 و بیماران مبتلا به HAM/TSP تعیین و سامانه ثبت متناظر آن توسعه داده شد که میتواند بستر مناسبی برای ثبت اطلاعات و دادههای مرتبط با HTLV-1 باشد.
واژههای کلیدی: ویروس لنفوتروپیک انسانی نوع ۱، HTLV-1، HAM-TSP، پاراپارزی اسپاستیک گرمسیری، سامانهی ثبت، مجموعه دادهی حداقلی
فهرست منابع
1. Gallo, R.C., History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2. Oncogene, 2005. 24(39): 30-59. [DOI:10.1038/sj.onc.1208980]
2. Gessain, A., et al., Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet, 1985. 2(8452): 10-407. [DOI:10.1016/S0140-6736(85)92734-5]
3. Taylor, G.P., et al., The seroepidemiology of human T-lymphotropic viruses: types I and II in Europe: a prospective study of pregnant women. J Acquir Immune Defic Syndr, 2005. 38(1): 9-104. [DOI:10.1097/00126334-200501010-00018]
4. Yamaguchi, K., Human T-lymphotropic virus type I in Japan. The Lancet, 1994. 343(8891): 216-213. [DOI:10.1016/S0140-6736(94)90994-6]
5. Proietti, F.A., et al., Global epidemiology of HTLV-I infection and associated diseases. Oncogene, 2005. 24(39): 68-6058. [DOI:10.1038/sj.onc.1208968]
6. Sherman, M.P., et al., Evolutionary insights on the origin of human T-cell lymphoma/leukemia virus type I (HTLV-I) derived from sequence analysis of a new HTLV-I variant from Papua New Guinea. J Virol, 1992. 66(4): 63-2556. [DOI:10.1128/jvi.66.4.2556-2563.1992]
7. Verdonck, K., et al., Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis, 2007. 7(4): 81-266. [DOI:10.1016/S1473-3099(07)70081-6]
8. de los Angeles Pando, M., et al., Human immunodeficiency virus type 1 and other viral co-infections among young heterosexual men and women in Argentina. Am J Trop Med Hyg, 2004. 71(2): 9-153. [DOI:10.4269/ajtmh.2004.71.153]
9. Vrielink, H. and H.W. Reesink, HTLV-I/II prevalence in different geographic locations. Transfus Med Rev, 2004. 18(1): 57-46. [DOI:10.1016/j.tmrv.2003.10.004]
10. Sharifi Razavi, A., et al., Human T-Lymphotropic Virus Type 1-Associated Myelopathy, or Tropical Spastic Paraparesis(HAM/TSP). Clinical Excellence, 2014. 2(2): 104-115.
11. Enose-Akahata, Y., A. Vellucci, and S. Jacobson, Role of HTLV-1 Tax and HBZ in the Pathogenesis of HAM/TSP. Frontiers in Microbiology, 2017. 8:25-63. [DOI:10.3389/fmicb.2017.02563]
12. DiMarco, G., D. Hill, and S.R. Feldman, Review of patient registries in dermatology. J Am Acad Dermatol, 2016. 75(4): 824-829. [DOI:10.1016/j.jaad.2016.03.020]
13. Ahmadi, M., et al., Developing a minimum data set of the information management system for orthopedic injuries in iran. Iran Red Crescent Med J, 2014. 16: 5-7. [DOI:10.5812/ircmj.17020]
14. Brooke, E.M. and O. World Health, The current and future use of registers in health information systems / Eileen M. Brooke, 1974, World Health Organization: Geneva.
15. Planning a Registry In: Gliklich RE, Dreyer NA, Leavy MB, editors. Registries for Evaluating Patient Outcomes: A User's Guide. 2014.
16. Evatt B. Guide to Developing a National Patient Registry 2005.
17. Abdelhak M, Grostick S, Hanken MA. Health Information: Management of a Strategic Resource. 3 ed: Elsevier Science Health Science Division; 2007.
18. Gould DJ. Minimum Data Set. In: Loue SJD, Sajatovic M, editors. Encyclopedia of Aging and Public Health. Boston, MA: Springer US; 2008. 568-569. [DOI:10.1007/978-0-387-33754-8_303]
19. Henry, P., et al., Developing a data dictionary for the irish nursing minimum dataset. Stud Health Technol Inform, 2006. 122: 503-510.
20. Toshach S. Best Practices for Data Dictionary Definitions and Usage. Version 1.1 ed:Northwest Environmental Data Network (NED) 2006.
21. Lee MK, Park H-A, Min YH, Kim Y, Min HK, Ham SW. Evaluation of the Clinical Data Dictionary (CiDD). Healthcare Informatics Research. 2010. [DOI:10.4258/hir.2010.16.2.82]
22. Hedayati-Moghaddam, M.R., et al., Epidemiology of HTLV-1 in Neyshabour, Northeast of Iran. Iranian Red Crescent medical journal. 2011. 13(6): 424-427.
23. Abbaszadegan, M.R., et al., Prevalence of human T-lymphotropic virus type 1 among blood donors from Mashhad, Iran. Journal of clinical microbiology. 2003. 41(6): 2593-2595. [DOI:10.1128/JCM.41.6.2593-2595.2003]
24. Rafatpanah, H., et al., High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol, 2011. 52(3): 172-176. [DOI:10.1016/j.jcv.2011.07.004]
25. Shoeibi, A., et al., Clinical features of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in northeast Iran. Acta Neurol Belg, 2013. 113(4): 427-433. [DOI:10.1007/s13760-013-0194-6]
26. Safabakhsh, H., M. Jalalian, and G. Karimi, Seroepidemiology of human T-cell lymphotropic virus type-1 (HTLV1) in Mashhad. Global journal of health science, 2014. 6(5): 99-104. [DOI:10.5539/gjhs.v6n5p99]
27. Satake, M., K. Yamaguchi, and K. Tadokoro, Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol, 2012. 84(2): 327-335. [DOI:10.1002/jmv.23181]
28. Hlela, C., et al., The prevalence of human T-cell lymphotropic virus type 1 in the general population is unknown. AIDS Rev, 2009. 11(4): 205-214.
29. Biswas, H.H., et al., Neurologic abnormalities in HTLV-I- and HTLV-II-infected individuals without overt myelopathy. Neurology, 2009. 73(10): 789-781. [DOI:10.1212/WNL.0b013e3181b6bba9]
30. Poetker, S.K.W., et al., Clinical manifestations in individuals with recent diagnosis of HTLV type I infection. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2011. 51(1): 54-58. [DOI:10.1016/j.jcv.2011.02.004]
31. Caskey, M.F., et al., Clinical manifestations associated with HTLV type I infection: a cross-sectional study. AIDS Res Hum Retroviruses, 2007. 23(3): 71-365. [DOI:10.1089/aid.2006.0140]
32. Castro, N.M., et al., Urodynamic features of the voiding dysfunction in HTLV-1 infected individuals. Int Braz J Urol, 2007. 33(2): 338-344. [DOI:10.1590/S1677-55382007000200016]
33. Nilla Olavarria, V., et al., Evolution of HTLV-1 proviral load in patients from Salvador, Brazil. The Brazilian Journal of Infectious Diseases, 2012. 16(4): 357-360. [DOI:10.1016/j.bjid.2012.06.022]
34. Carod-Artal, F.J., H.M. Mesquita, and S. Ribeiro Lda, [Neurological symptoms and disability in HTLV-1 associated myelopathy]. Neurologia, 2008. 23(2): 78-84.
35. Yukitake, M., et al., Significantly increased antibody response to heterogeneous nuclear ribonucleoproteins in cerebrospinal fluid of multiple sclerosis patients but not in patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol, 2008. 14(2): 130-135. [DOI:10.1080/13550280701883840]
36. Puccioni-Sohler, M., et al., HAM/TSP: association between white matter lesions on magnetic resonance imaging, clinical and cerebrospinal fluid findings. Arq Neuropsiquiatr, 2012. 70(4): 246-251. [DOI:10.1590/S0004-282X2012000400004]
37. Health information management technology. Tehran: Jafari Publication. 2012.
38. Walker, D.S., J.M. Visger, and A. Levi, Midwifery data collection: options and opportunities. J Midwifery Womens Health, 2008. 53(5): 421-429. [DOI:10.1016/j.jmwh.2008.04.002]
39. Sanderson, M. and J.F. Gonzalez, National Maternal and Infant Health Survey: methods and response characteristics. Vital Health Stat, 1998. 2(125): 1-39.
40. Matsumura, Y., et al., Proposal of diagnostic process model for computer based diagnosis. Stud Health Technol Inform, 2012. 180: 309-315.
41. Choquet, R., et al., A methodology for a minimum data set for rare diseases to support national centers of excellence for healthcare and research. J Am Med Inform Assoc, 2015. 22(1): 76-85. [DOI:10.1136/amiajnl-2014-002794]
42. Yaneva-Deliverska, M., PATIENT REGISTRIES FOR RARE DISEASES. Journal of IMAB - Annual Proceeding (Scientific Papers), 2016. 22. [DOI:10.5272/jimab.2016222.1166]
43. Taruscio, D., et al., The Italian National Rare Diseases Registry. Blood transfusion = Trasfusione del sangue, 2014. 3(3): 606-613.
44. Martins, A.M. and S.O. Kyosen, The importance of patient registries for rare diseases. Expert Opinion on Orphan Drugs, 2013. 1(10): 769-772. [DOI:10.1517/21678707.2013.840584]
45. Coler-Reilly, A.L.G., et al., Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net): Orphanet J Rare Dis. 2016. 11: 69. [DOI:10.1186/s13023-016-0451-x]
46. Geographical distribution of areas with a high prevalence of HTLV-1 infection.
47. darabi, m., et al., Designing the Minimum Data Set for Iranian Children' Health Records. journal of ilam university of medical sciences, 2016. 24(1): 114-125. [DOI:10.18869/acadpub.sjimu.24.1.114]
48. Hosseini A.S, Moghaddasi H, Jahanbakhsh Ma, Designing a minimum set of sweet diabetes data, the basis of effective indicators of diabetes management, Isfahan: Health Information Management,2010. 330- 340.
49. Dehghani, M., et al., Collection of Minimum Health Management Data in Crisis. Health Information Management, 2018. 15.
50. Jamali, A., M. Habibi, and R. Bagdizdel, Application of Delphi Method in Behavioral and Medical Sciences Research: A Review of Benefits, bottlenecks, and methodology. Higher Education Letter, 2014. 26 (7): 131-154.
51. Ahmadi, S.A. Roozbehani, Designing and compiling the performance audit model of the executive managers of state-owned banks. Journal of Public Accounting, 2018. 4 (2): 41-54.
52. McCann, L.J., et al., Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use. Trials, 2015. 16(228): 487-510. [DOI:10.1186/s13063-015-0784-0]
53. Naito, T., et al., Distinct gene expression signatures induced by viral transactivators of different HTLV-1 subgroups that confer a different risk of HAM/TSP. Retrovirology, 2018. 15(1): 454-810. [DOI:10.1186/s12977-018-0454-x]
54. Hashimoto, K., et al., Quantitative in situ PCR assay of HTLV-1 infected cells in peripheral blood lymphocytes of patients with ATL, HAM/TSP and asymptomatic carriers. J Neurol Sci, 1998. 159(1): 67-72. [DOI:10.1016/S0022-510X(98)00138-5]
55. Matsuura, E., et al., HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP): A comparative study to identify factors that influence disease progression. J Neurol Sci, 2016. 371: 112-116. [DOI:10.1016/j.jns.2016.10.030]
56. Kurai, J., et al., [Case of an HTLV-1 carrier complicated with chronic pulmonary histoplasmosis]. Nihon Kokyuki Gakkai Zasshi, 2008. 46(9): 737-742.
57. Yamano, Y., et al., Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP). Blood, 2002. 99(1): 88-94. [DOI:10.1182/blood.V99.1.88]
58. Guerreiro, J.B., et al., Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state. Clin Exp Immunol, 2006. 145(2): 296-301. [DOI:10.1111/j.1365-2249.2006.03150.x]
59. Saito, M., et al., Increased frequency of CD4+T cells expressing fractalkine receptor CX3CR1in patients with HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP), but its AIDS susceptible polymorphisms are not associated with the disease. J Neurol Sci, 2008. 266(1-2): 9-13. [DOI:10.1016/j.jns.2007.08.022]
60. Niederer, H.A., et al., HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP. Virol J, 2014. 11(172): 111-172. [DOI:10.1186/1743-422X-11-172]
61. Yari, A., et al., Evaluation of HTLV-1 activity in HAM/TSP patients using proviral load and Tax mRNA expression after In Vitro lymphocyte activation. Iran J Basic Med Sci, 2014. 17(7): 531-536.
62. Choquet, R., et al., A methodology for a minimum data set for rare diseases to support national centers of excellence for healthcare and research. J Am Med Inform Assoc, 2015. 22(1): 76-85. [DOI:10.1136/amiajnl-2014-002794]
63. Olindo, S., et al., Temporal trends in Human T-Lymphotropic virus 1 (HTLV-1) associated myelopathy/tropical spastic paraparesis (HAM/TSP) incidence in Martinique over 25 years (1986-2010). PLoS Negl Trop Dis, 2018. 12(3). [DOI:10.1371/journal.pntd.0006304]
64. Zamarshidi Fariba, "Study of Clinical and Extra-Clinical Findings of Patients with HTLV-I Neurological Complications, Referred to Ghaem Hospital Clinic during 2013-2014", Faculty of Medicine, 2014.
65. Assone, T., et al., Polymorphisms in HLA-C and KIR alleles are not associated with HAM/TSP risk in HTLV-1-infected subjects. Virus Res, 2018. 244: 71-74. [DOI:10.1016/j.virusres.2017.11.010]
66. Kitze, B., et al., Specificity of intrathecal IgG synthesis for HTLV-1 core and envelope proteins in HAM/TSP. Acta Neurol Scand, 1995. 92(3): 207-213. [DOI:10.1111/j.1600-0404.1995.tb01690.x]
67. Satow, Y., et al., [Virological studies on HTLV-1 carrier pregnant women]. Kansenshogaku Zasshi, 1997. 71(2): 136-142. [DOI:10.11150/kansenshogakuzasshi1970.71.136]
68. Greten, T.F., et al., Direct visualization of antigen-specific T cells: HTLV-1 Tax19-11- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci U S A, 1998. 95(13): 73-75. [DOI:10.1073/pnas.95.13.7568]
69. Saeidi, M., et al., Prevalence of peripheral neuropathy in patients with HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). Acta Neurol Belg, 2011. 111(1): 41-44.
70. Rajaei, T., et al., Different roles of CXCR1 and CXCR2 in HTLV-1 carriers and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. Med Microbiol Immunol, 2019. 208(5): 641-650. [DOI:10.1007/s00430-018-0568-8]
71. da Silva, J.L., et al., Clustering of HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) and infective dermatitis associated with HTLV-1 (IDH) in Salvador, Bahia, Brazil. J Clin Virol, 2013. 58(2): 482-485. [DOI:10.1016/j.jcv.2013.07.012]
72. Assone, T., et al., IL28B gene polymorphism SNP genotype GG is associated with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in HTLV-1 carriers. PLoS Negl Trop Dis, 2014. 8(9). [DOI:10.1371/journal.pntd.0003199]
73. Martins, M.L., et al., Long-term follow-up of HTLV-1 proviral load in asymptomatic carriers and in incident cases of HAM/TSP: what is its relevance as a prognostic marker for neurologic disease? J Neurovirol, 2017. 23(1): 125-133. [DOI:10.1007/s13365-016-0484-x]
74. Nakamura, F., et al., HTLV-1 associated myelopathy in an HTLV-1 and HBV double carrier family: report of a case and the mode of vertical transmission of both viruses. J Gastroenterol Hepatol, 1989. 4(4): 387-390. [DOI:10.1111/j.1440-1746.1989.tb00850.x]
75. Nakamura, M., et al., Elevated antibodies to synthetic peptides of HTLV-1 envelope transmembrane glycoproteins in patients with HAM/TSP. J Neuroimmunol, 1991. 35(3-1): 167-177. [DOI:10.1016/0165-5728(91)90171-3]
76. Nakamura, M., et al., Increase of peripheral B lymphocytes committed to the production of monoreactive and high affinity antibodies to HTLV-1in patients with HAM/TSP. J Neuroimmunol, 1992. 37(2-1): 35-45. [DOI:10.1016/0165-5728(92)90153-C]
77. Araujo Ade, Q., et al., Clinical and demographic features of HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Rio de Janeiro, Brazil. Acta Neurol Scand, 1993. 88(1): 59-62. [DOI:10.1111/j.1600-0404.1993.tb04188.x]
78. Izumo, S., et al., Neuropathology of HTLV-1-associated myelopathy (HAM/TSP). Leukemia, 1997. 3: 82-84.
79. Shimojima, Y., et al., Mixed connective tissue disease with interstitial pneumonia in HTLV-1carrier: case report and review of the literature. Clin Rheumatol, 2004. 23(6): 548-551. [DOI:10.1007/s10067-004-0955-y]
80. Best, I., et al., Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru. Clin Exp Immunol, 2006. 146(2): 326-333. [DOI:10.1111/j.1365-2249.2006.03208.x]
81. Best, I., et al., IFN-gamma production in response to Tax 233-161, and frequency of CD4+ Foxp3+ and Lin HLA-DRhigh CD123+ cells, discriminate HAM/TSP patients from asymptomatic HTLV-1-carriers in a Peruvian population. Immunology, 2009. 128(1): 1365-2567. [DOI:10.1111/j.1365-2567.2009.03082.x]
82. Netto, E.C. and C. Brites, Characteristics of Chronic Pain and Its Impact on Quality of Life of Patients With HTLV-1-associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). Clin J Pain, 2011. 27(2): 131-135. [DOI:10.1097/AJP.0b013e3181f195d3]
83. de Souza, J.G., et al., Anti-Tax antibody levels in asymptomatic carriers, oligosymptomatic carriers, patients with rheumatologic disease or with HAM/TSP do not correlate with HTLV-1 proviral load. J Clin Virol, 2011. 50(1): 8-13. [DOI:10.1016/j.jcv.2010.09.007]
84. Grassi, M.F., et al., Human T cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP. J Med Virol, 2011. 83(7): 1269-1274. [DOI:10.1002/jmv.22087]
85. Sarkis, S., et al., Increased osteopontin expression in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patient cells is associated with IL-17 expression. J Clin Virol, 2013. 58(1): 295-298. [DOI:10.1016/j.jcv.2013.05.006]
86. Trevino, A., et al., Association between HLA alleles and HAM/TSP in individuals infected with HTLV-1. J Neurol, 2013. 260(10): 2551-1555. [DOI:10.1007/s00415-013-7014-z]
87. Ami, Y., et al., Vertical transmission of HTLV-1 in HTLV-11carrier rat. Jpn J Cancer Res, 1992. 83(12): 1241-1243. [DOI:10.1111/j.1349-7006.1992.tb02751.x]
88. Kazi, A., et al., Deleted HTLV-1 provirus in cord-blood samples of babies born to HTLV-1-carrier mothers. Int J Cancer, 1998. 77(5): 701-704.
https://doi.org/10.1002/(SICI)1097-0215(19980831)77:5<701::AID-IJC7>3.3.CO;2-D [DOI:10.1002/(SICI)1097-0215(19980831)77:53.3.CO;2-D]
89. Suzuki, S., et al., Instruction of feeding methods to Japanese pregnant women who cannot be confirmed as HTLV-1 carrier by western blot test: J Matern Fetal Neonatal Med. 2014. 27(13): 1392-1393. [DOI:10.3109/14767058.2013.852175]
90. Grindstaff, P. and G. Gruener, The peripheral nervous system complications of HTLV-1 myelopathy (HAM/TSP) syndromes. Semin Neurol. 2005. 25(3): 315-327. [DOI:10.1055/s-2005-917668]
91. Saito, M., Immunogenetics and the Pathological Mechanisms of Human T-Cell Leukemia VirusType 1- (HTLV-1-)Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). Interdiscip Perspect Infect Dis, 2010. 461-478. [DOI:10.1155/2010/478461]
92. Oliveira, P.D., A.C. Kachimarek, and A.L. Bittencourt, Early Onset of HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) and Adult T-cell Leukemia/Lymphoma (ATL): Systematic Search and Review. J Trop Pediatr, 2018. 64(2):b151-161. [DOI:10.1093/tropej/fmx039]
93. Fujii, N., Y. Itoh, and H. Tomoda, Disseminated herpes zoster with multifocal neurologic involvement in an HTLV-1 carrier. Intern Med, 1993. 32(11): 854-856. [DOI:10.2169/internalmedicine.32.854]
94. Saito, M., et al., Mutation rates in LTR of HTLV-1 in HAM/TSP patients and the carriers are similarly high to Tax/Rex-coding sequence. J Neurovirol, 1996. 2(5): 330-335. [DOI:10.3109/13550289609146897]
95. Atarashi, K., et al., Recurrent histiocytic necrotizing lymphadenitis (Kikuchi's disease) in an human T lymphotropic virus type I carrier. Intern Med, 1996. 35(10): 821-825. [DOI:10.2169/internalmedicine.35.821]
96. Koya, Y., et al., Establishment of a seronegative human T-cell leukemia virus type 1 (HTLV-1) carrier state in rats inoculated with a syngeneic HTLV-1-immortalized T-cell line preferentially expressing Tax. J Virol, 1999. 73(8): 43-64. [DOI:10.1128/JVI.73.8.6436-6443.1999]
97. Iniguez, A.M., et al., Genetic markers on the HTLV-1 p12I protein sequences from Brazilian HAM/TSP patients and asymptomatic HTLV-1 carrier isolates. AIDS Res Hum Retroviruses, 2005. 21(6): 580-582. [DOI:10.1089/aid.2005.21.580]
98. Kunisada, M., et al., Nasal-type natural killer cell lymphoma preceded by benign panniculitis arising in an asymptomatic HTLV-1 carrier. Int J Dermatol, 2003. 42(9): 710-714. [DOI:10.1046/j.1365-4362.2003.01757.x]
99. Satoh, M., et al., Severe strongyloidiasis complicated by meningitis and hydrocephalus in an HTLV-1 carrier with increased proviral load. J Infect Chemother, 2003. 9(4): 355-357. [DOI:10.1007/s10156-003-0272-4]
100. Harada, M., et al., A human T-cell lymphotropic virus type-1 (HTLV-1) carrier complicated with various autoimmune diseases including primary biliary cirrhosis. Hepatol Res, 2005. 31(2): 116-119. [DOI:10.1016/j.hepres.2004.12.003]
101. Echevarria-Lima, J., et al., Protein Profile of Blood Monocytes is Altered in HTLV-1 Infected Patients: Implications for HAM/TSP Disease. Sci Rep, 2018. 8(1): 323-324. [DOI:10.1038/s41598-018-32324-2]
102. Martins, M.L., et al., HTLV-1 proviral load in cerebrospinal fluid may not be a good marker to differentiate asymptomatic carriers with high proviral load in blood from HAM/TSP patients. J Neurovirol, 2018. 24(4): 432-438. [DOI:10.1007/s13365-018-0632-6]
103. Matsuura, E., et al., Clinical presentation of axial myopathy in two siblings with HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). BMC Neurol, 2018. 15(18): 510-575. [DOI:10.1186/s12883-015-0275-7]
104. Kozuru, M., et al., AILD-like dysplasia transformed in AILD-type T cell lymphoma in an HTLV-1 carrier: usefulness of interferon-alpha. Acta Haematol, 1996. 96(2): 92-98. [DOI:10.1159/000203723]
105. Tokura, Y., et al., Human T-lymphotropic virus 1 (HTLV-1)-associated lichenoid dermatitis induced by CD8+ T cells in HTLV-1 carrier, HTLV-1-associated myelopathy/tropical spastic paraparesis and adult T-cell leukemia/lymphoma. J Dermatol, 2015. 42(10): 967-974. [DOI:10.1111/1346-8138.12980]
106. Ishikawa, N., et al., KL-6 as an indicator for lymphocytic interstitial pneumonia (LIP) in a human T-lymphotrophic virus type 1 (HTLV-1) carrier. Ann Hematol, 2002. 81(8): 474-477. [DOI:10.1007/s00277-002-0465-4]
107. Barreto, F.K., et al., Analyses of HTLV-1 sequences suggest interaction between ORF-I mutations and HAM/TSP outcome. Infect Genet Evol, 2016. 45: 420-425. [DOI:10.1016/j.meegid.2016.08.020]
108. Wu, X.M., et al., Flow cytometric differentiation of Asian and Western types of multiple sclerosis, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and hyperIgEaemic myelitis by analyses of memory CD4 positive T cell subsets and NK cell subsets. J Neurol Sci, 2000. 177(1): 24-31. [DOI:10.1016/S0022-510X(00)00322-1]
109. Levin, M.C., et al., Localization of retrovirus in the central nervous system of a patient co-infected with HTLV-1 and HIV with HAM/TSP and HIV-associated dementia. J Neurovirol, 2001. 7(1): 61-65. [DOI:10.1080/135502801300069719]
110. Belrose, G., et al., Effects of valproate on Tax and HBZ expression in HTLV-1 and HAM/TSP T lymphocytes. Blood, 2011. 118(9): 2483-2491. [DOI:10.1182/blood-2010-11-321364]
111. Starling, A.L., et al., Proviral load and the balance of serum cytokines in HTLV-1-asymptomatic infection and in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Acta Trop, 2013. 125(1): 75-81. [DOI:10.1016/j.actatropica.2012.09.012]
112. Mota-Miranda, A.C., et al., Molecular characterization of HTLV-1 gp46 glycoprotein from health carriers and HAM/TSP infected individuals. Virol J, 2013. 10(75): 10-75. [DOI:10.1186/1743-422X-10-75]
113. Yamano, Y. and A. Coler-Reilly, HTLV-1 induces a Th1-like state in CD4(+)CCR4(+) T cells that produces an inflammatory positive feedback loop via astrocytes in HAM/TSP. J Neuroimmunol, 2017. 304: 51-55. [DOI:10.1016/j.jneuroim.2016.08.012]
114. Colaco, C.S., et al., Downregulation of histone methyltransferase EHMT2 in CD4(+) T-cells may protect HTLV-1-infected individuals against HAM/TSP development. Arch Virol, 2017. 162(10): 3131-3136. [DOI:10.1007/s00705-017-3428-8]
115. Ishigaki, T., et al., Development of peripheral T-cell lymphoma not otherwise specified in an HTLV-1 carrier. Int J Hematol, 2013. 97(5): 667-672. [DOI:10.1007/s12185-013-1314-z]
116. Ramirez, E., L. Cartier, and R. Flores, In vitro cytoskeleton changes of mouse neurons induced by purified HTLV-1, and PBMC from HAM/TSP patients and HTLV-1 carriers. Arch Virol, 2004. 149(12): 2307-2317. [DOI:10.1007/s00705-004-0387-7]
117. Saito, M., et al., In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology, 2009. 6(19): 1742-4690. [DOI:10.1186/1742-4690-6-19]
118. Raza, S.M. and J.R. Pyatt, Nocturnal hypertension and autonomic dysfunction due to human T-lymphotropic virus type-1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP): Int J Cardiol. 2006. 107(3): 424-426. [DOI:10.1016/j.ijcard.2005.02.010]
ارسال پیام به نویسنده مسئول
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
